InSphero AG
June 24, 2026
Theater 3
Type: Company Presentation
Focus Area:
Gastrointestinal
InSphero is the global leader in 3D cell-based assay and organ-on-chip technologies for preclinical drug discovery and safety testing. With labs in the US and Switzerland, the company partners with 18 of the top 20 pharmaceutical companies to deliver scalable, biologically predictive in vitro models that advance the adoption of New Approach Methodologies.
Our gastrointestinal portfolio pairs standardized intestinal organoids with high-throughput assay formats, enabling robust efficacy and safety testing of compounds acting on the GI tract. Built on the Gri3D platform, these models reproduce intestinal barrier function, drug absorption, and toxicity responses with the reproducibility that regulatory and industrial workflows demand.
By turning organoid science into reliable, scalable assays, InSphero helps drug developers decide earlier, with greater confidence, while reducing reliance on animal testing.
Company HQ City:
Schlieren
Company HQ State:
ZH
Company HQ Country:
Switzerland
Year Founded:
2009
Lead Product in Development:
GI and IBD solutions
CEO
Jan Lichtenberg
Development Phase of Lead Product
Pre-Clinical
Number of Unlicensed Products Looking for Licensing
3
When you expect your next catalyst update?
2027
What is your next catalyst (value inflection) update?
FDA filing
Primary Speaker
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}